General
Preferred name
RILPIVIRINE
Synonyms
TMC278 ()
R278474 ()
DB08864 ()
TMC 278. trade name Edurant ()
AQUIPTA ()
RILPIVIRINE HYDROCHLORIDE ()
TMC278 hydrochloride ()
TMC-278 hydrochloride ()
Rilpivirine (hydrochloride) ()
TMC-278 (hydrochloride) ()
TMC278 (hydrochloride) ()
TMC 278 (hydrochloride) ()
R278474, TMC278, DB08864 ()
Rilpivirine HCl ()
Rilpivirine ()
Rilpivirina ()
R-278474 ()
Rekambys ()
Edurant ()
TMC-278 ()
R 278474 ()
Rilpivirine component of cabenuva ()
Rilpivirine hydrochloride component of eviplera ()
Rilpivirine hydrochloride component of complera ()
Edurant ped ()
Rilpivirine (as hydrochloride) ()
TMC-278 HYDROCHLORIDE ()
Rilpivirine hcl ()
TMC278 HYDROCHLORIDE ()
Rilpivirine hydrochloride component of odefsey ()
Rilpivirine hydrochloride component of juluca ()
Rilpivirine-d6 (hydrochloride) ()
P&D ID
PD004299
CAS
500287-72-9
700361-47-3
Tags
available
drug
Approved by
PMDA
FDA
First approval
2011
Drug indication
Pain
Human immunodeficiency virus infection
HIV infection
HIV-1 infection
Drug Status
approved
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Rilpivirine is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI) HIV medication. (GtoPdb)
DESCRIPTION Rilpivirine (R278474) is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine has a high genetic barrier to resistance development of HIV[1][2].
PRICE 63
DESCRIPTION Rilpivirine (R278474) hydrochloride is a potent and specific diarylpyrimidine (DAPY) non-nucleoside reverse transcriptase inhibitor (NNRTI). Rilpivirine hydrochloride has high antiviral activity against wild-type HIV (EC50=0.4 nM) and mutant viruses (EC50=0.1-2.0 nM). Rilpivirine hydrochloride has a high genetic barrier to resistance development of HIV[1][2].
PRICE 57
DESCRIPTION Rilpivirine (R278474) is a diarylpyrimidine derivative and reverse transcriptase inhibitor with antiviral activity against HIV-1 that is used in the treatment of HIV infections. (TargetMol Bioactive Compound Library)
DESCRIPTION Rilpivirine HCl (Rilpivirine hydrochloride) is a selective and potent non-nucleoside reverse transcriptase inhibitor (NNRTI) with antiviral activity that inhibits the HIV virus and can be used in the study of HIV infections. (TargetMol Bioactive Compound Library)
Cell lines
1
Organisms
4
Compound Sets
19
AdooQ Bioactive Compound Library
A11542
Cayman Chemical Bioactives
21559
26520
ChEMBL Approved Drugs
CHEMBL175691
CHEMBL1628504
ChEMBL Drugs
CHEMBL175691
CHEMBL1628504
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB08864
DrugBank Approved Drugs
DB08864
DrugCentral
4174
DrugCentral Approved Drugs
4174
DrugMAP
DMJ0QOW
DrugMAP Approved Drugs
DMJ0QOW
EU-OPENSCREEN Bioactive Compound Library
EOS100150
Guide to Pharmacology
11387
MedChem Express Bioactive Compound Library
HY-10574
HY-10574A
NCATS Inxight Approved Drugs
FI96A8X663
ReFrame library
Selleckchem Bioactive Compound Library
rilpivirine
rilpivirine-hydrochloride
TargetMol Bioactive Compound Library
T2330
T2330L
External IDs
62
Properties
(calculated by RDKit )
Molecular Weight
366.16
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
5
Ring Count
3
Aromatic Ring Count
3
cLogP
4.99
TPSA
97.42
Fraction CSP3
0.09
Chiral centers
0.0
Largest ring
6.0
QED
0.62
Structural alerts
2
aggregator (Aggregator Advisor)
Aggregators
aggregator (ZINC)
Aggregators
Related compounds
Custom attributes
(extracted from source data)
Target
HIV
Reverse Transcriptase
SARS-CoV
MMP
NR1I2, SCN10A
Indication
human immunodeficiency virus (HIV-1)
MOA
non-nucleoside reverse transcriptase inhibitor
Pathway
Anti-infection
Metabolic Enzyme/Protease
Microbiology/virology
Proteases/Proteasome
Source data